Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells

Prostate

Volumn 71, Issue 3, 2011, Pages 298-304

  Yokomizo, Akira ^a   Shiota, Masaki ^a   Kashiwagi, Eiji ^a   Kuroiwa, Kentaro ^a   Tatsugami, Katsunori ^a   Inokuchi, Junichi ^a   Takeuchi, Ario ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

androgen receptor; prostate cancer; prostate specific antigen; statin

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COMPACTIN; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; GENE EXPRESSION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; DIHYDROTESTOSTERONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTOR, IGF TYPE 1; RECEPTORS, ANDROGEN;

EID: 78751496139     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21243     Document Type: Article

References (21)

1. Ma J, Sehgal NL, Ayania JZ, Stafford RS,. National trends in statin use by coronary heart disease risk category. PLoS Med 2005; 2: e123.
2. Shannon J, Tewoderos S, Garzotto M, Bee TM, Derenick R, Palma A, Farris PE,. Statins and prostate cancer risk: A case-control study. Am J Epidemiol 2005; 162: 318-325.
3. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE,. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213-2217.
4. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ,. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218-2225.
5. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ,. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1511-1518.
6. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL,. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250-260.
7. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S,. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene 2010; 29: 237-250.
8. Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, Kidani A, Hirano G, Masubuchi D, Fukunaka Y, Yasuniwa Y, Naito S, Nishizawa S, Sasaguri Y, Kohno K,. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69: 3148-3156.
9. Tomura A, Goto K, Morinaga H, Nomura M, Okabe T, Yanase T, Takayanagi R, Nawata H,. The subnuclear three-dimensional image analysis of androgen receptor fused to green fluorescence protein. J Biol Chem 2001; 276: 28395-28401.
10. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K, Uchiumi T, Fujimoto N, Seki N, Naito S,. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol 2010; 24: 114-127.
11. Shiota M, Yokomizo A, Masubuchi D, Tada Y, Inokuchi J, Eto M, Uchiumi T, Fujimoto N, Naito S,. Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 2010; 70: 540-554.
12. Mener DJ, Cambio A, Stoddard DG, Martin BA, Palapattu GS,. The impact of HMG-CoA reductase therapy on serum PSA. Prostate 2010; 70: 608-615.
13. Sekine Y, Furuya Y, Nishii M, Koike H, Matsui H, Suzuki K,. Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 2008; 372: 356-361.
14. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ,. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-5386.
15. Hong MY, Seeram NP, Zhang Y, Heber D,. Chinese red yeast rice versus lovastatin effects on prostate cancer cells with and without androgen receptor overexpression. J Med Food 2008; 11: 657-666.
16. Igel M, Sudhop T, von Bergmann K,. Pharmacology of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002; 42: 835-845.
17. Hall SA, Page ST, Travison TG, Montgomery RB, Link CL, McKinlay JB,. Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007; 16: 1587-1594.
18. Dobs AS, Miller S, Neri G, Weiss S, Tate AC, Shapiro DR, Musliner TA,. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000; 49: 115-121.
19. Carruba G,. Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007; 102: 899-911.
20. Murtola TJ, Pennanen P, Syvala H, Blauer M, Ylikomi T, Tammela TL,. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 2009; 69: 1017-1023.
21. Tang YQ, Han BM, Yao XQ, Hong Y, Wang Y, Zhao FJ, Yu SQ, Sun XW, Xia SJ,. Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells. Asian J Androl 2009; 11: 119-126.